Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLSL Pharma Group Inc.

LSL Pharma Group Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.31 CAD 0.01 ( 1.64%)
Last update at 2026-11-04T20:15:00Z
VOLUME
1501
Market Cap
50.31M
P/E
20.75

Momentum Score

…

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health products in liquid and semi-solid form for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.30
Low
0.31
High
52 Week Price Range
0.33
Low
0.56
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

LSL Pharma Group Inc. is a Vancouver-listed company (TSX-V: LSL) with limited public disclosure; it appears positioned in the pharmaceutical sector but details on products, clinical programs or operations are sparse. Long-term growth may be driven by successful product development, regulatory approvals, licensing or commercial partnerships and geographic expansion, and investors may find potential upside if management executes on those milestones.

Primary investment risks include limited transparency, early-stage or unclear assets, high regulatory and execution risk, low trading liquidity and the likely need for additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.30
Dividend Yield
-
Revenue TTM
26.80M
Revenue Per Share
0.23
Gross Profit TTM
7.97M
Debt / Equity
-
ROE
12.13%
Net Debt
16.47M
ROCE
0.93%
Diluted EPS TTM
0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 3.37M -8.47M -8.06M -1.63M 0.08M
Net income 3.32M -8.47M -8.06M -1.78M 0.09M
Selling general administrative 4.76M 5.39M 3.83M 2.59M 0.61M
Gross profit 5.35M 1.65M -2.17M 2.53M 0.51M
Reconciled depreciation 1.51M 1.13M 1.05M 0.97M 0.37M
Operating income 0.41M -3.95M -6.76M -0.07M 0.81M
Interest expense 1.75M 1.57M 1.27M 1.59M 0.53M
Tax provision 0.05M - - 0.15M -0.01M
Interest income - - - 0.00M 0.01M
Net interest income -1.90M -1.76M -1.39M -1.71M -0.73M
Total revenue 17.75M 10.03M 8.21M 8.77M 4.82M
Total operating expenses 17.34M 13.98M 14.97M 8.84M 4.01M
Cost of revenue 12.40M 8.38M 10.39M 6.25M 4.32M
Total other income expense net 4.86M -2.76M 0.08M 0.14M -
Net income from continuing ops 3.32M -8.47M -8.06M -1.78M 0.09M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 53.51M 30.90M 27.31M 29.03M 23.79M
Intangible assets 13.27M 8.93M - 9.39M 9.91M
Total liab 28.62M 22.25M 22.02M 17.92M 16.31M
Total stockholder equity 24.89M 8.65M 5.29M 11.11M 7.48M
Other current liab - - 1.04M 1.46M 1.18M
Capital stock 36.39M 24.20M 15.05M 12.81M 7.56M
Retained earnings -14.92M -18.23M -9.76M -1.70M -0.08M
Good will 0.16M - - - -
Cash 0.30M 0.01M 0.00M 0.74M 0.46M
Total current liabilities 9.65M 15.07M 11.62M 7.25M 11.81M
Net debt 16.47M 13.71M 12.16M 9.13M 8.87M
Short long term debt 4.01M 8.98M 4.31M 1.89M 5.83M
Total current assets 15.38M 7.20M 4.39M 6.48M 3.92M
Net receivables 4.80M 2.55M 0.96M 1.12M 1.55M
Long term debt 12.75M 4.73M 7.84M 7.98M 3.51M
Inventory 9.12M 4.11M 2.96M 4.17M 1.64M
Accounts payable 4.50M 4.92M 4.54M 2.54M 2.47M
Non current assets total 38.13M 23.70M 22.92M 22.55M 19.87M
Capital lease obligations 4.87M 2.56M 2.70M 2.87M 1.23M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - -1.02M -1.00M -1.04M -1.19M
Net borrowings 3.51M - - - -
Total cash from financing activities 9.40M 8.10M 3.42M 0.94M 1.74M
Net income 3.32M -8.47M -8.06M -1.78M 0.09M
Change in cash 0.29M 0.01M -0.74M -1.18M 0.43M
Begin period cash flow 0.01M 0.00M 0.74M 1.93M 0.03M
End period cash flow 0.30M 0.01M 0.00M 0.74M 0.46M
Total cash from operating activities -1.65M -7.07M -3.16M -1.08M -0.12M
Issuance of capital stock 8.23M 9.46M 2.37M 2.65M 3.23M
Depreciation 1.51M 1.13M 1.05M 0.97M 0.37M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory -1.77M - - -2.04M -0.38M
Change to account receivables -0.51M - - 0.96M -0.36M
Capital expenditures 4.20M 1.02M 1.00M 0.91M 0.09M
Change in working capital -3.98M -4.74M 2.97M -1.99M -0.38M
Stock based compensation 0.42M 2.12M 0.00M - -
Other non cash items -2.96M 2.90M 0.88M 1.56M -0.19M
Free cash flow -5.85M -8.09M -4.16M -2.00M -0.20M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LSL
LSL Pharma Group Inc.		 0.01
1.64%		 0.31 20.75 - 1.88 1.89 2.85 10.19
RX
Biosyent Inc.		 0.30
1.78%		 17.15 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.21
11.67%		 2.01 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
ROMJ
Rubicon Organics Inc		 0.04
10.67%		 0.41 28.50 38.02 0.65 0.87 0.79 9.17

Profile*

LSL Pharma Group Inc.

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health products in liquid and semi-solid form for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.

540, d?Avaugour Street, Boucherville, QC, Canada, J4B 0G6

514 664 7700

https://www.groupelslpharma.com

186

Name Title Year Born
Mr. Francois Roberge Chairman, President & CEO 1965
Marc Boudreault Vice-President of Communications NA
Ms. Mélanie St-Pierre CFA Corporate Controller NA
Mr. Luc Mainville M.B.A, M.B.A. CFO & Director 1964
Mr. Francois Roberge President, CEO & Director 1965
Mr. Francis Chenard Senior VP & COO NA
Mr. Guy Paul Allard Vice President, Legal Affairs & Corporate Secretary NA
Ms. Sylvie Laplante Vice President of Quality & Compliance NA
Mr. Luc Mainville M.B.A. CFO & Senior VP 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…